1 Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases.

2 Therapeutic effects of Cyperus rotundus rhizome extract on memory impairment, neurogenesis and mitochondria in beta-amyloid rat model of Alzheimer's disease.

3 Sulforaphane attenuates Aβ oligomers mediated decrease in phagocytic activity of microglial cells.

4 Brain health INnovation Diplomacy: a model binding diverse disciplines to manage the promise and perils of technological innovation.

5 Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.

6 multi-target anti-alzheimer activities of four prenylated compounds from psoralea fructus

7 Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review

8 Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer’s Disease

9 Impaired Cerebral Vasomotor Reactivity in Alzheimer’s Disease

10 Alzheimer’s Disease Mortality according to Socioeconomic Factors: Country Study

11 Alzheimer’s Disease Frontal Cortex Mitochondria Show a Loss of Individual Respiratory Proteins but Preservation of Respiratory Supercomplexes

12 Development of Regional Disparities in Alzheimer’s Disease Mortality in the Slovak Republic from 1996 to 2015

13 Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease

14 Investigation of Cerebral Hemodynamic Changes in Mild Cognitive Impairment Due to Alzheimer’s Disease During a Verbal Fluency Task

15 Dysfunction of the ubiquitin ligase E3A Ube3A/E6-AP contributes to synaptic pathology in Alzheimer’s disease

16 Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

17 Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

18 Visualizing Alzheimer’s Disease Mouse Brain with Multispectral Optoacoustic Tomography using a Fluorescent probe, CDnir7

19 Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model

20 Blockade of α4 integrins reduces leukocyte–endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer’s disease

21 Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease

22 Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice

23 Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease

24 Reversibility of Age-related Oxidized Free NADH Redox States in Alzheimer’s Disease Neurons by Imposed External Cys/CySS Redox Shifts

25 Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model

26 Acute restraint stress reverses impaired LTP in the hippocampal CA1 region in mouse models of Alzheimer’s disease

27 Screening older adults for amnestic mild cognitive impairment and early-stage Alzheimer’s disease using upper-extremity dual-tasking

28 Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease

29 Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches

30 Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease

31 Polygenic impact of common genetic risk loci for Alzheimer’s disease on cerebral blood flow in young individuals

32 Cognitive decline in normal aging and early Alzheimer’s disease: A continuous or discontinuous transition? A historical review and future research proposal

33 Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer’s disease from healthy individuals

34 Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer’s disease

35 Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism

36 Correction to: New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer’s disease

37 In silico analysis of green tea polyphenols as inhibitors of AChE and BChE enzymes in alzheimer’s disease treatment

38 Effectiveness of Group Cognitive-Behavioral Therapy on Strategies for Coping With Stress of Family Caregivers of Patients With Alzheimer’s Disease

39 Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response

40 Different patterns of hippocampal tau pathology in Alzheimer’s disease and PART

41 Emphasis Learning, Features Repetition in Width Instead of Length to Improve Classification Performance: Case Study—Alzheimer’s Disease Diagnosis

42 Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease

43 A Novel Scheme for the Early Diagnosis of Alzheimer’s Disease through MRI Analysis

44 Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease

45 A Web-Based Psychoeducational Program for Informal Caregivers of Patients With Alzheimer’s Disease: A Pilot Randomized Controlled Trial

46 Evaluating the Efficacy of a Web-Based Program (Diapason) for Informal Caregivers of Patients With Alzheimer’s Disease: Protocol for a Randomized Clinical Trial

47 Amyloid and tau in the brain in sporadic Alzheimer’s disease: defining the chicken and the egg

48 A Web-Based Program for Informal Caregivers of Persons With Alzheimer’s Disease: An Iterative User-Centered Design

49 Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer’s disease

50 The role of pro-inflammatory S100A9 in Alzheimer’s disease amyloid-neuroinflammatory cascade

51 High-Dose Cholinergic Therapy With Rivastigmine Patch Does Not Prolong QTc Time in Patients With Alzheimer’s Disease

52 Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain

53 Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold

54 Commentary: Alzheimer’s Disease: Implications of the Updated Diagnostic and Research Criteria

55 Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer’s disease

56 Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model

57 Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer’s disease

58 A life dedicated to Alzheimer’s disease research: in memory of Inge Grundke-Iqbal (1937–2012)

59 On the origin of tau seeding activity in Alzheimer’s disease

60 a chinese herbal formula, gengnianchun, ameliorates β-amyloid peptide toxicity in a caenorhabditis elegans model of alzheimer’s disease

61 the role of micrornas in aβ deposition and tau phosphorylation in alzheimer’s disease

62 is sleep disruption a cause or consequence of alzheimer’s disease? reviewing its possible role as a biomarker

63 detection of bacterial antigens and alzheimer’s disease-like pathology in the central nervous system of balb/c mice following intranasal infection with a laboratory isolate of chlamydia pneumoniae

64 resting state bold variability in alzheimer’s disease: a marker of cognitive decline or cerebrovascular status?

65 beneficial effect of multidomain cognitive training on the neuropsychological performance of patients with early-stage alzheimer’s disease

66 evaluation of cholinergic deficiency in preclinical alzheimer’s disease using pupillometry

67 crispr/cas9 mediated disruption of the swedish app allele as a therapeutic approach for early-onset alzheimer’s disease

68 seeking a new paradigm for alzheimer’s disease: considering the roles of inflammation, blood-brain barrier dysfunction, and prion disease

69 altered behavioral and autonomic pain responses in alzheimer’s disease are associated with dysfunctional affective, self-reflective and salience network resting-state connectivity

70 early cortical changes in gamma oscillations in alzheimer’s disease

71 esc-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with alzheimer’s disease in mouse models

72 back to the fusion: mitofusin-2 in alzheimer’s disease

73 cerebrovascular-reactivity mapping using mri: considerations for alzheimer’s disease

74 multi factorial interactions in the pathogenesis pathway of alzheimer’s disease: a new risk charts for prevention of dementia

75 neuroprotection and neurodegeneration in alzheimer’s disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans

76 improved diagnostic multimodal biomarkers for alzheimer’s disease and mild cognitive impairment

77 successful therapies for alzheimer’s disease: why so many in animal models and none in humans?

78 mir-103 promotes neurite outgrowth and suppresses cells apoptosis by targeting prostaglandin-endoperoxide synthase 2 in cellular models of alzheimer’s disease

79 aquaporin-4 reduces neuropathology in a mouse model of alzheimer’s disease by remodeling peri-plaque astrocyte structure

80 ligand-based and structure-based investigation for alzheimer’s disease from traditional chinese medicine

81 opinion: an evaluation of progressive amyloidogenic and pro-inflammatory change in the primary visual cortex and retina in alzheimer’s disease (ad)

82 predicting cerebral amyloid angiopathy-realated intracerebral hemorrhages and other cerebrovascular disorders in alzheimer’s disease

83 studying micro rna (mirna) function and dysfunction in alzheimer’s disease

84 evaluating promis physical function measures in older adults at risk for alzheimer’s disease

85 deep brain stimulation as a tool for improving cognitive functioning in alzheimer’s dementia: a systematic review

86 enhancing resourcefulness to improve outcomes in family caregivers and persons with alzheimer’s disease: a pilot randomized trial

87 different temporal patterns of specific and general autobiographical memories across the lifespan in alzheimer’s disease

88 diabetes and hypertension, as well as obesity and alzheimer’s disease, are linked to hypohydration-induced lower brain volume

89 effective artifact removal in resting state fmri data improves detection of dmn functional connectivity alteration in alzheimer’s disease

90 insulin resistance and alzheimer’s disease: bioenergetic linkages

91 a peephole into the brain: neuropathological features of alzheimer’s disease revealed by in vivo two-photon imaging

92 index of alpha/theta ratio of the electroencephalogram: a new marker for alzheimer’s disease

93 benefits of psychodynamic group therapy on depression, burden and quality of life of family caregivers to alzheimer’s disease patients

94 differential contributions of apoe4 and female sex to bace1 activity and expression mediate aβ deposition and learning and memory in mouse models of alzheimer’s disease

95 proof-of-concept randomized controlled study of cognition effects of the proprietary extract sceletium tortuosum (zembrin) targeting phosphodiesterase-4 in cognitively healthy subjects: implications for alzheimer’s dementia

96 differential roles of environmental enrichment in alzheimer’s type of neurodegeneration and physiological aging

97 neuroprotective effect of fagopyrum dibotrys extract against alzheimer’s disease

98 alzheimer’s disease diagnosis by detecting exogenous fluorescent signal of ligand bound to beta amyloid in the lens of human eye: an exploratory study

99 genetics of alzheimer’s disease: lessons learned in two decades

100 a systems view of the differences between apoe ε4 carriers and non-carriers in alzheimer’s disease

101 alzheimer’s transgenic model is characterized by very early brain network alterations and β-ctf fragment accumulation: reversal by β-secretase inhibition

Keyword Connections

Journals

Research Groups

Bibliographies